In people with suspected heart failure who also have chronic kidney disease, what is the clinical and cost effectiveness of N-terminus pro-B-type natriuretic peptide (NT-proBNP) compared to B-type natriuretic peptide (BNP), when each is followed by the appropriate patient pathway, in order to improve patient outcomes?
No clinical evidence was identified for this review question, and no relevant economic evaluations were identified. To answer this question, single gate studies (cohort/cross-sectional) should be conducted to determine the diagnostic accuracy of BNP and NT-proBNP, including measures such as specificity, sensitivity, PPV/NPV, and the area under the ROC curve.